Moreover, we wanted to validate the clinical relevance of miR-221/222 expression in prostate tumors, and thus we measured the expression of these two microRNAs in primary cells from 18 patients with stage II–III prostate cancer, and concurrently quantified p27 expression, to check if the inverse relationship linking miR-221/222 to p27 is reproducible and significant in clinical samples. The gene discussed is CDKN1B; the disease is prostate cancer.